Dupilumab efficacy and safety in Japanese patients with uncontrolled, moderate-to-severe asthma in the phase 3 LIBERTY ASTHMA QUEST study

Dupilumab efficacy and safety in Japanese patients with uncontrolled, moderate-to-severe asthma in the phase 3 LIBERTY ASTHMA QUEST study

Background: In the LIBERTY ASTHMA QUEST (ClinicalTrials.gov: NCT02414854) study, dupilumab 200 mg and 300 mg every 2 weeks vs matched-volume placebo reduced severe asthma exacerbations and improved lung function (FEV1), asthma control, and quality of life in patients with uncontrolled, moderate-to-s...

Full description

Bibliographic Details
Main Authors: Yuji Tohda, Yoichi Nakamura, Takao Fujisawa, Motohiro Ebisawa, Kazuhiko Arima, Masanori Miyata, Yoshinori Takahashi, Megan S. Rice, Yamo Deniz, Paul Rowe, Naimish Patel, Neil M.H. Graham, Ariel Teper
Format: Article
Language:English
Published: Elsevier 2020-10-01
Series:Allergology International
Subjects:
Dupilumab
Exacerbation
Forced expiratory volume
Japanese
Moderate-to-severe asthma
Online Access:http://www.sciencedirect.com/science/article/pii/S1323893020300526

Internet

http://www.sciencedirect.com/science/article/pii/S1323893020300526

Similar Items